

**AMENDMENTS TO THE CLAIMS:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

1-26 (canceled).

27 (currently amended). ~~A 1,2,4-benzotriazine-1,4-dioxide compound of Formula I as claimed in claim 24 selected from~~

~~$N^1,N^1$ -Dimethyl- $N^2$ -(6-methyl-1,4-dioxide-1,2,4-benzotriazin-3-yl)-1,2-ethanediamine;~~

~~6-Methyl- $N$ -[3-(4-morpholinyl)propyl]-1,2,4-benzotriazin-3-amine 1,4-dioxide;~~  
 ~~$N^1$ -(6-Methoxy-1,4-dioxide-1,2,4-benzotriazin-3-yl)- $N^2,N^2$ -dimethyl-1,2-ethanediamine;~~

~~$N^1$ -[6-(2-Methoxyethoxy)-1,4-dioxide-1,2,4-benzotriazin-3-yl]- $N^2,N^2$ -dimethyl-1,2-ethanediamine;~~

~~$N^1,N^1$ -Dimethyl- $N^2$ -(6-ethoxy-1,4-dioxide-1,2,4-benzotriazin-3-yl)-1,2-ethanediamine;~~

~~6-Ethyl- $N$ -[3-(4-morpholinyl)propyl]-1,2,4-benzotriazin-3-amine 1,4-dioxide;~~  
~~2-[(3-Ethyl-1,4-dioxide-1,2,4-benzotriazin-6-yl)oxy]- $N,N$ -dimethylethaneamine;~~  
~~3-Ethyl-6-[3-(4-morpholinyl)propoxy]-1,2,4-benzotriazine 1,4-dioxide;~~  
~~6-Methyl-1,2,4-benzotriazin-3-amine 1,4-dioxide; and~~  
~~their pharmacologically acceptable salts thereof.~~

28 (currently amended). A method of therapy for treating cancer including comprising the step of administering a 1,2,4-benzotriazine-1,4-dioxide compound of ~~Formula I~~ as claimed in claim 24-27 in a therapeutically effective amount to tumour cells in a subject, wherein the tumour cells are in a hypoxic environment.

29 (canceled).

30 (currently amended). The method as claimed in claim 28 further including the step of administering radiotherapy to the tumour cells before, during or after the administration of the 1,2,4-benzotriazine-1,4-dioxide compound of ~~Formula I~~ as defined above in claim 27 to the tumour cells.

31 (currently amended). The method as claimed in claim 30 further including the step of administering one or more chemotherapeutic agents to the tumour cells before, during or after the administration of the 1,2,4-benzotriazine-1,4-dioxide compound of ~~Formula I~~ as defined above in claim 27 to the tumour cells.

32 (currently amended). The method as claimed in claim 31 wherein the one or more chemotherapeutic agents is selected from Cisplatin or other platinum-based derivatives, Temozolomide or other DNA methylating agents, cyclophosphamide or other DNA alkylating agents, Doxorubicin, mitoxantrone, camptothecin or other topoisomerase inhibitors, Methotrexate, gemcitabine or other antimetabolites and/or Docetaxel or other taxanes.

33 (currently amended). A method of radiosensitising in a subject tumour cells of solid tumours in hypoxic conditions in vivo, comprising the steps of:

(a) administering to the subject a pharmaceutical composition in an amount sufficient to produce radiosensitivity in the tumour cells, the composition comprising a ~~1,2,4-benzotriazine-1,4-dioxide~~ compound as claimed in claim 24 27; and

(b) subjecting the tumour cells to radiation.

34-35 (canceled).

36 (currently amended). A pharmaceutical composition including comprising a therapeutically effective amount of a ~~1,2,4-benzotriazine-1,4-dioxide~~ of Formula I compound as defined in claim 24 27 and a pharmaceutically acceptable excipient, adjuvant, carrier, buffer or stabiliser.